leisure time -WSS

leisure time

author：knowledge 2025-08-04 12:29:52 - browse：8874

Illustration: Alex Hogan/STAT; Photo: Courtesy Perrigo

It’s not every day that a marketing team is tasked with designing the branding and packaging of the first over-the-counter birth control pill to be sold in the U.S.

This was the challenge, and the opportunity, faced by the team behind Opill, the landmark pill from drugmaker Perrigo that received approval from the Food and Drug Administration earlier this month. Their brief: Create a design that would stand out in America’s notoriously sprawling pharmacy aisles; inspire trust and confidence; be easy to remember and recognize; appeal to women — including teenagers — as well as trans men and nonbinary people; clearly communicate its purpose; be simple to carry and use; contain straightforward but accurate user information; and clear FDA requirements.

Settling on the right approach took years of research and testing, which resulted in the name Opill and packaging featuring bright teal, saturated pink, and yellow, as well as a rounded font reminiscent of millennials’ ubiquitous favorite Gotham. All of these features are intended to set the product apart from the dozens of prescription contraceptive pills available in the U.S. market and internationally.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： STAT wants to know your pick for a great summer read or listen

explore

WSS

Prescription digital therapeutics are key to pharma’s future

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

A public health expert passes on football's full body collisions for youths

Bispecific antibodies are next new thing in cancer immunotherapy

Novo pauses ads for weight loss drug Wegovy amid demand

Lupron, used to halt puberty in children, may cause lasting health problems

explore

leisure time

entertainment

Alkermes shareholders re

Security flaws in third

As demand for Covid shots wanes, Moderna seeks its next success

A letter from the executive editor: The 2023 STATUS List

Jerome Adams on the need for new antivirals for Covid

Fatty liver disease was alleviated by Lilly’s ‘triple

Duchenne breakthrough therapy leaves behind pioneering families

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

What does generative AI mean for health care? We asked experts

Biogen nominates mother of director’s child to replace him on board

hotspot

Timeline: Key moments in fight for gay rights

FDA approves first new drug developed for postpartum depression

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Fatty liver disease was alleviated by Lilly’s ‘triple

hotspot

explore

leisure time

focus